Literature DB >> 1940996

Impairment of physical and psychosocial function in recurrent syncope.

M Linzer1, M Pontinen, D T Gold, G W Divine, A Felder, W B Brooks.   

Abstract

Physical and psychosocial function have rarely been assessed in syncope. We used two valid and reliable measures of health status, the Sickness Impact Profile (SIP) and the Symptom Checklist 90 (SCL-90-R), to assess functional impairment in 62 patients with recurrent syncope seen in a syncope specialty clinic. Mean total SIP scores were markedly elevated at 17 (SD = 14), indicating a level of impairment similar to severe rheumatoid arthritis and chronic low back pain. SIP psychosocial scores were significantly greater than SIP physical scores (20 vs 11, p less than 0.0001). SCL-90-R scores were also high, comparable to those of psychiatric inpatients. Somatization, anxiety and depression dimensions of the SCL-90-R were particularly elevated. SCL-90-R subscale scores were highly correlated with SIP psychosocial scores (all r greater than 0.4, and p less than 0.001). Neither age nor number of comorbid diseases correlated with measures of psychosocial function, suggesting that syncope itself causes psychosocial impairment. Although this was a referral population, these data suggest that function can be seriously impaired by syncope, that the degree of impairment is similar to that reported in other chronic diseases, and that syncope leads to significantly greater psychosocial than physical impairment.

Entities:  

Mesh:

Year:  1991        PMID: 1940996     DOI: 10.1016/0895-4356(91)90005-t

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  49 in total

1.  Vasodepressor Syncope.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-08

2.  Reflex syncope in children and adolescents.

Authors:  Wouter Wieling; Karin S Ganzeboom; J Philip Saul
Journal:  Heart       Date:  2004-09       Impact factor: 5.994

Review 3.  New insight on the molecular mechanisms of high-density lipoprotein cellular interactions.

Authors:  L O Martinez; S Jacquet; F Tercé; X Collet; B Perret; R Barbaras
Journal:  Cell Mol Life Sci       Date:  2004-09       Impact factor: 9.261

4.  [Commentary on the guidelines the diagnosis and the therapy of syncope--the European Society of Cardiology 2001 and the update 2004].

Authors:  K Seidl; A Schuchert; J Tebbenjohanns; W Hartung
Journal:  Z Kardiol       Date:  2005-09

Review 5.  How to avoid a misdiagnosis in patients presenting with transient loss of consciousness.

Authors:  Sanjiv Petkar; Paul Cooper; Adam P Fitzpatrick
Journal:  Postgrad Med J       Date:  2006-10       Impact factor: 2.401

Review 6.  Concepts of scientific integrative medicine applied to the physiology and pathophysiology of catecholamine systems.

Authors:  David S Goldstein
Journal:  Compr Physiol       Date:  2013-10       Impact factor: 9.090

7.  Guidelines for the diagnosis and management of syncope (version 2009).

Authors:  Angel Moya; Richard Sutton; Fabrizio Ammirati; Jean-Jacques Blanc; Michele Brignole; Johannes B Dahm; Jean-Claude Deharo; Jacek Gajek; Knut Gjesdal; Andrew Krahn; Martial Massin; Mauro Pepi; Thomas Pezawas; Ricardo Ruiz Granell; Francois Sarasin; Andrea Ungar; J Gert van Dijk; Edmond P Walma; Wouter Wieling
Journal:  Eur Heart J       Date:  2009-08-27       Impact factor: 29.983

Review 8.  Diagnostic value of history taking in reflex syncope.

Authors:  N Colman; K Nahm; J G van Dijk; J B Reitsma; W Wieling; H Kaufmann
Journal:  Clin Auton Res       Date:  2004-10       Impact factor: 4.435

Review 9.  Nonpharmacological treatment of reflex syncope.

Authors:  Wouter Wieling; Nancy Colman; C T Paul Krediet; Roy Freeman
Journal:  Clin Auton Res       Date:  2004-10       Impact factor: 4.435

10.  Preliminary observations on the use of closed-loop cardiac pacing in patients with refractory neurocardiogenic syncope.

Authors:  Khalil Kanjwal; Beverly Karabin; Yousuf Kanjwal; Blair P Grubb
Journal:  J Interv Card Electrophysiol       Date:  2009-11-25       Impact factor: 1.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.